<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6359">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670903</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-8336-DS-CTIL</org_study_id>
    <nct_id>NCT01670903</nct_id>
  </id_info>
  <brief_title>The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients</brief_title>
  <official_title>the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal aortic aneurysm (AAA)  is a common disease that  develops from degeneration of the
      aortic wall. The natural history of AAA is gradual expansion and if left untreated may
      result in rupture and death. The mechanism of the development of this disease is unknown
      however it appears to be multifactorial and possibly related to degradation processes within
      the arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may
      have an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting
      degeneration of the vessel wall.

      Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive
      patients, and are associated with a lower rate of aortic expansion compared to other
      antihypertensive drugs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aneurysm</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ARBs</arm_group_label>
    <description>Hypertensive patients treated with ARBs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE inhibitors</arm_group_label>
    <description>Hypertensive patients treated with ACE inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non ARB/ACE</arm_group_label>
    <description>Hypertensive patients treated with non ARBs or ACE inhibitors meds</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        medically treated hypertensive patients, ages 50-80
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically treated hypertensive patients, ages 50-80

        Exclusion Criteria:

          -  pregnant women

          -  patients previously treated for aortic disease

          -  unable to sign informed consent, minors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Silverberg, MD</last_name>
    <phone>035302712</phone>
    <email>Daniel.Silverberg@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacob Schneiderman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehud Grossman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moshe Halak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anan Younes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitry Yakubovitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bashir Sheik-yosef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronnie E Reinitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Silverberg, MD</last_name>
      <email>Daniel.Silverberg@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 19, 2012</lastchanged_date>
  <firstreceived_date>August 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Daniel Silverberg</investigator_full_name>
    <investigator_title>Senior consultant - Vascular surgery</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
